111 related articles for article (PubMed ID: 327758)
1. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
Enger SC; Johnsen V; Samuelsen A; Laws EA
Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
[TBL] [Abstract][Full Text] [Related]
2. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.
Lithell H; Boberg J; Hedstrand H; Hellsing K; Ljunghall S; Vessby B
Eur J Clin Pharmacol; 1977 Aug; 12(1):51-7. PubMed ID: 332503
[No Abstract] [Full Text] [Related]
3. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
[TBL] [Abstract][Full Text] [Related]
5. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
Schwandt P; Weisweiler P; Neureuther G; Wilkening J
MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
[TBL] [Abstract][Full Text] [Related]
6. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.
Kobayashi M; Shigeta Y; Hirata Y; Omori Y; Sakamoto N; Nambu S; Baba S
Diabetes Care; 1988 Jun; 11(6):495-9. PubMed ID: 3042317
[TBL] [Abstract][Full Text] [Related]
7. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
[TBL] [Abstract][Full Text] [Related]
8. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus.
Ferrari C; Romussi M; Bertazzoni A; Testori GP; Grimaldi MG
Biomedicine; 1978 Jun; 29(4):133-6. PubMed ID: 556385
[TBL] [Abstract][Full Text] [Related]
9. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
[TBL] [Abstract][Full Text] [Related]
10. Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.
Murakami K; Nambu S; Koh H; Kobayashi M; Shigeta Y
Br J Clin Pharmacol; 1984 Jan; 17(1):89-91. PubMed ID: 6362704
[TBL] [Abstract][Full Text] [Related]
11. Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
Bagdade JD; Bierman EL; Porte D
Diabetes; 1971 Oct; 20(10):664-72. PubMed ID: 5110698
[No Abstract] [Full Text] [Related]
12. Metabolic effects of clofibrate in insulin-dependent ketosis-prone diabetic man.
Schade DS; Eaton RP; George S; Conway M; Kaminsky N; Sivinski J
Metabolism; 1978 Apr; 27(4):461-8. PubMed ID: 416322
[TBL] [Abstract][Full Text] [Related]
13. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes.
Ferrari C; Testori GP; Bertazzoni A; Romussi M; Caldara R; Frezzati S
Horm Metab Res; 1978 Jan; 10(1):4-6. PubMed ID: 631736
[TBL] [Abstract][Full Text] [Related]
14. Effect of clofibrate on glucose tolerance in maturity onset diabetes.
Barnett D; Craig JG; Robinson DS; Rogers MP
Br J Clin Pharmacol; 1977 Aug; 4(4):455-8. PubMed ID: 901737
[TBL] [Abstract][Full Text] [Related]
15. [Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia. Behavior of plasma lipids, glucose tolerance, and plasma insulin after glucose load during treatment with clofibrate].
Bruns W; Rjasanowski I; Wulfert P; Michael R; Knospe S; Hildmann W
Endokrinologie; 1974 Nov; 64(1):2-12. PubMed ID: 4466653
[No Abstract] [Full Text] [Related]
16. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
Feldman EB; Gluck FB; Carter AC
J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
[TBL] [Abstract][Full Text] [Related]
17. [Effect of clofibrate on glucide tolerance in patients with ischemic heart disease and hyperlipoproteinemia].
Bornemisza P; Csögör I
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1978; 30(6):543-6. PubMed ID: 34860
[No Abstract] [Full Text] [Related]
18. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus.
Calvert GD; Blight L; Franklin J; Oliver J; Wise P; Gallus AS
Eur J Clin Pharmacol; 1980 May; 17(5):355-62. PubMed ID: 6998709
[No Abstract] [Full Text] [Related]
19. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia.
Eaton BP; Nye WH
J Lab Clin Med; 1973 May; 81(5):682-95. PubMed ID: 4349136
[No Abstract] [Full Text] [Related]
20. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
[No Abstract] [Full Text] [Related]
[Next] [New Search]
